Log in

Guided Therapeutics Stock Forecast, Price & News

+0.00 (+0.63 %)
(As of 10/21/2020 03:38 PM ET)
Today's Range
Now: $0.40
50-Day Range N/A
52-Week Range
Now: $0.40
Volume17,700 shs
Average Volume16,259 shs
Market Capitalization$5.27 million
P/E RatioN/A
Dividend YieldN/A
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was founded in 1992 and is based in Norcross, Georgia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.20 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolOTCMKTS:GTHP
Phone770 242 8723



Sales & Book Value

Annual Sales$40,000.00
Book Value($5.35) per share


Net Income$-1,920,000.00


Market Cap$5.27 million
Next Earnings Date3/8/2021 (Estimated)
OptionableNot Optionable
+0.00 (+0.63 %)
(As of 10/21/2020 03:38 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GTHP News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Guided Therapeutics (OTCMKTS:GTHP) Frequently Asked Questions

When is Guided Therapeutics' next earnings date?

Guided Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Guided Therapeutics

How were Guided Therapeutics' earnings last quarter?

Guided Therapeutics, Inc. (OTCMKTS:GTHP) released its quarterly earnings results on Wednesday, August, 19th. The company reported ($0.06) earnings per share for the quarter.
View Guided Therapeutics' earnings history

Are investors shorting Guided Therapeutics?

Guided Therapeutics saw a drop in short interest during the month of September. As of September 30th, there was short interest totaling 400 shares, a drop of 91.8% from the September 15th total of 4,900 shares. Based on an average daily volume of 5,500 shares, the short-interest ratio is currently 0.1 days.
View Guided Therapeutics' Short Interest

Who are some of Guided Therapeutics' key competitors?

Who are Guided Therapeutics' key executives?

Guided Therapeutics' management team includes the following people:
  • Dr. Gene S. Cartwright, CEO, Pres, Acting CFO & Director (Age 66)
  • Dr. Mark L. Faupel, COO, Sec. & Director (Age 65)
  • Mr. Richard L. Fowler, Sr. VP of Engineering and Sec. (Age 64)

What is Guided Therapeutics' stock symbol?

Guided Therapeutics trades on the OTCMKTS under the ticker symbol "GTHP."

How do I buy shares of Guided Therapeutics?

Shares of GTHP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Guided Therapeutics' stock price today?

One share of GTHP stock can currently be purchased for approximately $0.40.

How big of a company is Guided Therapeutics?

Guided Therapeutics has a market capitalization of $5.27 million and generates $40,000.00 in revenue each year. Guided Therapeutics employs 5 workers across the globe.

What is Guided Therapeutics' official website?

The official website for Guided Therapeutics is www.guidedinc.com.

How can I contact Guided Therapeutics?

Guided Therapeutics' mailing address is 5835 PEACHTREE CORNERS EAST SUITE D, PEACHTREE CORNERS GA, 30092. The company can be reached via phone at 770 242 8723 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.